Barbexaclone

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.^[2] It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"^[3] had not yet been confirmed nor denied in controlled trials.

Barbexaclone

Combination of
Phenobarbital	Barbiturate
Levopropylhexedrine	Sympathomimetic
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N03AA04 (WHO)
Legal status
Legal status	BR: Class B1 (Psychoactive drugs)[1] US: Schedule IV
Identifiers
CAS Number	4388-82-3 Y
PubChem CID	71196
DrugBank	DB09001 N
ChemSpider	64332 Y
UNII	291GX1YB65
CompTox Dashboard (EPA)	DTXSID90195974
ECHA InfoCard	100.022.278
NY (what is this?)  (verify)

Potency

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.^[2]